β-Amyloid (1-9), an N-terminal fragment of beta amyloid, consists of amino acid residues 1 to 9. β-Amyloid (1-9) contains a B cell epitope, but it does not include T cell epitopes. Omission of residues 1 to 9 from the full-length Alzheimer'sβ-Amyloid peptide 1 to 40 does not prevent the peptide from forming amyloid fibrils or eliminate fibril polymorphism .
β-Amyloid 1-9 is a synthetic peptide fragment derived from the N-terminal region of the amyloid beta (Aβ) protein, which is widely studied for its crucial role in neurodegenerative disease research, particularly in the context of Alzheimer's disease pathology. As a well-defined peptide segment, it encompasses the first nine amino acids of the Aβ sequence, providing a valuable tool for dissecting the molecular mechanisms underlying amyloid formation, protein-protein interactions, and immunogenicity. Its defined sequence and structural properties make it a versatile reagent for a range of peptide-based investigations, enabling researchers to explore the biochemical and biophysical properties of amyloidogenic peptides in controlled experimental settings.
Aggregation studies: The N-terminal peptide fragment is frequently utilized in aggregation assays to examine the initial steps of amyloid fibril formation. By isolating the first nine residues, researchers can investigate the contribution of this segment to the nucleation process, oligomerization, and the overall aggregation kinetics of Aβ peptides. Such studies are fundamental for understanding how specific sequence motifs influence the propensity for misfolding and self-assembly, which are central to amyloid pathobiology.
Epitope mapping: In immunological research, β-Amyloid 1-9 serves as a key reagent for mapping antibody epitopes and characterizing the specificity of monoclonal antibodies raised against amyloid beta. By providing a defined N-terminal sequence, this peptide fragment allows for precise determination of antibody binding sites, supporting the development and validation of novel immunoassays. Such applications are essential for generating highly selective detection reagents and for advancing the study of immune responses to amyloidogenic proteins.
Peptide-protein interaction analysis: The segment is widely employed in studies aimed at elucidating the molecular interactions between amyloid beta and other cellular or extracellular proteins. Its use in binding assays and structural analyses helps clarify how the N-terminal domain of Aβ engages with chaperones, receptors, or modulators of amyloidogenesis. These insights contribute to a deeper understanding of the molecular determinants that govern amyloid beta's pathological and physiological roles.
Analytical standards: As a chemically defined peptide, β-Amyloid 1-9 provides a reliable standard for analytical techniques such as high-performance liquid chromatography (HPLC), mass spectrometry, and capillary electrophoresis. Its use as a reference material enables accurate quantification, calibration, and validation of analytical methods employed in peptide research, ensuring reproducibility and comparability across laboratories.
Peptide synthesis and modification studies: The N-terminal fragment is also valuable as a substrate or starting material for chemical modification, labeling, or extension in solid-phase peptide synthesis workflows. Researchers often utilize it to generate longer amyloid beta sequences, introduce site-specific modifications, or attach reporter groups for downstream applications. These capabilities facilitate the creation of tailored peptide probes and conjugates for advanced biochemical and biophysical investigations.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More